TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01294800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 2, 5, or 10 mg tablets taken orally twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 2, 5, or 10 mg tablets taken orally twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: 2, 5, or 10 mg tablets taken orally twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet to match Preladenant
Description: tablets taken orally BID
Study: NCT02268058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: routine administration of medication for a 72 hour period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: routine administration of medication for a 72 hour period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: routine administration of medication for a 72 hour period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: routine administration of medication for a 72 hour period
Study: NCT01098071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate nasal spray
Description: One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
Study: NCT01913392

Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Study: NCT02491255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve System
Description: Device: Lotus Valve System
Study: NCT02263833

Intervention type: DRUG
Intervention: Mircera
Description: Participants received Mircera according to individualized physician-prescribed regimen.
Study: NCT00942474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facilitate nerve stimulation lead placement with the nerve access tool
Study: NCT00870064

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Formal Operative Treatment
Description: Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Emergency Department Treatment
Description: Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
Study: NCT02706873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Capsule or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Methotrexate
Description: Capsule or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Methotrexate
Description: Capsule or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Methotrexate
Description: Capsule or Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral
Study: NCT02412293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education & Promotion
Description: Promotion of antenatal care, adequate nutrition, skilled delivery and healthy newborn care practices at household level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of Health Workers
Description: Training of health workers on recognition of danger sign that warrant referral to health care service.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization
Description: Community mobilization activities included formation of community health committees and creation of support for the uptake of the interventions.
Study: NCT04612998

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: left lateral decubitus position
Description: Comparator group consisted of patients performing CSEA in the left lateral decubitus position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sitting position
Description: Active control group consisted of patients performing CSEA in the sitting position.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The use of intravenous ephedrine.
Description: Intravenous ephedrine (6 mg) was used to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) during surgery.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: The use of intravenous ephedrine.
Description: Intravenous ephedrine (6 mg) was used to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The use of intravenous atropine.
Description: Intravenous atropine (1 mg) was given in case of bradycardia (the heart rate \< 45 beats/minute) during surgery.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: The use of intravenous atropine.
Description: Intravenous atropine (1 mg) was given in case of bradycardia (the heart rate \< 45 beats/minute) during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The use of intravenous metoclopramide
Description: When nausea and vomiting were observed, intravenous metoclopramide (10 mg) was administered.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: The use of intravenous metoclopramide
Description: When nausea and vomiting were observed, intravenous metoclopramide (10 mg) was administered.
Study: NCT02929264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: Capsules, 40 mg, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, single dose
Study: NCT02205060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality exposure treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive and behavioral approaches therapy
Study: NCT01381783

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phacoemulsification
Description: Phacoemulsification under topical anesthesia
Study: NCT03322059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals). They will also receive a donation to a cancer charity of their choice if they meet daily step goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals).
Study: NCT01558661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (AXITINIB)
Description: All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) \> 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
Study: NCT01555203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: liveWell: A healthy foundation for life
Description: liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.~In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI.
Study: NCT04344678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Esitalopram 20 mg tablet plus placebo tablet once daily
Study: NCT01045980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioimpedance and Vitamin D
Description: Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual care and placebo
Description: Usual care (not bioimpedance guided volume management) and Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual care and Vitamin D
Description: Usual care (not bioimpedance guided volume management) and Vitamin D

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance and Placebo
Description: Bioimpedance guided volume management and Placebo
Study: NCT00785330

Intervention type: DRUG
Group type: OTHER
Intervention: standard GVHD prophylaxis
Description: Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
Study: NCT01441752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
Study: NCT01100944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXD101with cisplatin+doxorubicin+cyclophosphamide
Description: PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
Study: NCT03705715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET with radiotracer [11C]PBR-28 ( or [11C]ER176)
Description: \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET with radiotracer [11C]PBR-28 ( or [11C]ER176)
Description: \[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affective challenge
Description: Affective challenge is the induction of, for example, mood or affective pain.
Study: NCT02090712

Intervention type: PROCEDURE
Intervention: PCI
Description: Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction

Intervention type: PROCEDURE
Intervention: PCI
Description: Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
Study: NCT00739414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: 10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
Study: NCT03714490

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCPRT
Description: Short-course preoperative radiotherapy(SCPRT), which consists of 5 Gy x 5f and 4Gy for boost on the GTV with MRI-simulation alone.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: Long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: Patients will receive consolidation chemotherapy after 7-10 days of SCPRT completed, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are scheduled before surgery.
Study: NCT01017107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated protein C
Description: 24 micrograms/kg/hour intravenously for 96 hours
Study: NCT01378286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARTESUNATE + AMODIAQUINE
Description: Pharmaceutical form:~Route of administration:

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT03423342

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nicotinamide riboside
Description: nicotinamide riboside capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule
Study: NCT01665807

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intanza
Description: Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intanza
Description: Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxigrip
Description: Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
Study: NCT01515774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirapex ER
Description: Change Requip or Mirapex to Mirapex ER

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirapex ER
Description: Change Requip or Mirapex to Mirapex ER
Study: NCT04342728

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Readily available marketed open label ascorbic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Gluconate
Description: Readily available marketed open label zinc gluconate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid and Zinc Gluconate
Description: Readily available marketed open label ascorbic acid and zinc gluconate

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Readily available prescribed medications/ supplements- None study supplements
Study: NCT03541005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Obex
Description: After concluded the six months of treatment, patients will be follow-up during six months without consumption of Obex

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After concluded the six months of treatment, patients will be follow-up during six months without consumption of the placebo.
Study: NCT04358783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma
Description: The plasma unit will be fractionated in 200 mL aliquots for storage at -80°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Available Therapy
Description: It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.
Study: NCT01997879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution, 0.02%
Description: Eyedrop
Study: NCT05019001

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laminoplasty
Description: A posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laminectomy With Fusion
Description: Another posterior approach surgical method to treat patients with Ossification of the Posterior Longitudinal Ligament
Study: NCT01014832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Description: Intensive insulin therapy
Study: NCT01046877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy Tube Delivery System
Description: Placement of the Tympanostomy Tube by the Acclarent Tympanostomy Tube Delivery System (TTDS)
Study: NCT00035594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pegfilgrastim
Description: Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.
Study: NCT00726466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab, Ranibizumab
Study: NCT00608985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zolpidem
Description: 2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
Study: NCT05786092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Monitoring of the required parameters by means of the data provided by the devices used by patients. The data (weight, body composition, blood pressure, oxygen saturation, physical activity, heart rate and blood glucose) collected according to the predetermined schedule are then saved in a cloud accessible to researchers.
Study: NCT01637545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room~G3 - No medication but regular antiemetics injection if the patient want

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room~G3 - No medication but regular antiemetics injection if the patient want

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room~G3 - No medication but regular antiemetics injection if the patient want
Study: NCT00197054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS, S/AS01B
Description: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and liposomes in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS, S/AS02A
Description: 0.5mL dose; 50ug RTS, S antigen, 50ug QS21 and proprietary oil-water emulsion in phosphate-buffered saline administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabipur (Rabies) Vaccine
Description: 1.0mL dose administered intramuscular deltoid of non-dominant arm at 0, 1 and 2 months
Study: NCT00191451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).~Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion).